MedTrace Logo

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

NCT07105254 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-08-08

No results posted yet for this study

Summary

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Conditions

  • Non-segmental Vitiligo

Interventions

DRUG

Roflumilast topical 0.3% foam

Roflumilast 0.3% topical foam

Sponsors & Collaborators

  • Arcutis Biotherapeutics, Inc.

    collaborator INDUSTRY

  • Derm Texas, PLLC

    lead NETWORK

Principal Investigators

  • Kelly Warren, MD · Derm Texas, PLLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-05-15
Completion
2026-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07105254 on ClinicalTrials.gov